文献速递真菌感染

泊沙康唑血药浓度与假性高醛固酮症相关

Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism.
PubMed 文献 · Clin Infect Dis · 2020-01-01

这项单中心回顾性观察研究纳入69例新开始泊沙康唑的门诊患者,16例(23.2%)符合假性高醛固酮症(PIPH)定义。PIPH患者血泊沙康唑浓度中位数显著更高(3.0 vs 1.2 µg/mL,P ≤ .0001),且年龄更大、基线高血压更多。结论认为泊沙康唑可致继发性高血压和低钾血症,符合假性高醛固酮症,其发生与较高血药浓度、年龄较大和基线高血压相关。

要点

  • 泊沙康唑可致继发性高血压与低钾血症,符合假性高醛固酮症。
  • PIPH患者泊沙康唑血药浓度中位数显著高于无PIPH者(3.0 vs 1.2 µg/mL)。
  • 年龄较大和基线高血压者发生PIPH的风险更高。

核心结论

  • 泊沙康唑与继发性高血压和低钾血症相关,符合假性高醛固酮症,其发生与较高血清泊沙康唑浓度、年龄较大和基线高血压相关。

研究设计与样本

  • 单中心、回顾性、观察性研究,纳入69例新开始泊沙康唑的门诊患者,比较有无PIPH者的血清泊沙康唑浓度和临床特征。

主要发现

  • 69例中16例(23.2%)符合PIPH定义。
  • PIPH患者年龄显著更大(61.1 vs 44.7岁,P = .007),基线高血压比例更高(68.8% vs 32.1%,P = .009)。
  • PIPH患者血清泊沙康唑浓度中位数显著更高(3.0 vs 1.2 µg/mL,P ≤ .0001)。
  • 血清泊沙康唑浓度与收缩压变化正相关(r = .37,P = .01),与血清钾变化负相关(r = -.39,P = .006),与血清11-脱氧皮质醇正相关(r = .69,P < .0001)。

临床怎么用

  • 对使用泊沙康唑的患者,尤其年龄较大或基线高血压者,应监测血压、血钾和泊沙康唑血药浓度。

局限性

  • 单中心、回顾性、观察性设计,样本量69例,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Posaconazole tablets are well tolerated and efficacious in the prophylaxis and treatment of aspergillosis, mucormycosis, and other invasive fungal infections. There have been case reports of posaconazole-induced pseudohyperaldosteronism (PIPH); however, its occurrence and association with serum posaconazole drug levels have not previously been investigated. METHODS: In this single-center, retrospective, observational study, we examined the occurrence of PIPH in outpatients newly starting posaconazole and evaluated differences in serum posaconazole concentrations and clinical characteristics between those with and without this syndrome. RESULTS: Sixty-nine patients receiving posaconazole were included, of whom 16 (23.2%) met the definition of PIPH. Patients with PIPH were significantly older (61.1 vs 44.7 years, P = .007) and more frequently had hypertension prior to starting posaconazole (68.8% vs 32.1%, P = .009). Patients with PIPH had a significantly higher median serum posaconazole level than those without PIPH (3.0 vs 1.2 µg/mL, P ≤ .0001). There was a positive correlation between serum posaconazole levels and changes in systolic blood pressure (r = .37, P = .01), a negative correlation between serum posaconazole levels and changes in serum potassium (r = -.39, P = .006), and a positive correlation between serum posaconazole levels and serum 11-deoxycortisol (r = .69, P < .0001). CONCLUSIONS: Posaconazole is associated with secondary hypertension and hypokalemia, consistent with pseudohyperaldosteronism, and development is associated with higher serum posaconazole concentrations, older age, and baseline hypertension.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Nguyen MH, Davis MR, Wittenberg R, et al. Posaconazole Serum Drug Levels Associated With Pseudohyperaldosteronism. Clin Infect Dis. 2020. PMID: 31403165. doi:10.1093/cid/ciz741

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。